Accordingly, pharmacological inhibitors or specific antisense oligonucleotides inhibiting STAT6 have shown interesting properties in vitro as well as in animal models to limit liver fibrosis or HCC occurrence/progression. This evidence concerns the gene STAT6 and hepatocellular carcinoma.